// App-Quantinova.ai

10677 : Dapagliflozin in Patients With Type 2 Diabetes and Established Cardiovascular Disease: Hypotension and Volume-related Safety

Researchers

Presenter

  • Lawrence A. Leiter

Principal Investigators

  • William T. Cefalu

  • Ingrid Gause-Nilsson

  • Eva Johnsson

  • Shamik J Parikh

Medical Centers

  • Louisiana State University, Monroe, LA.

  • St. Michael's Hosp, Toronto, ON, Canada

Locations

  • United States

  • Canada

Companies

  • AstraZeneca plc

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • Congestive heart failure

  • Type 2 diabetes mellitus

  • Orthostatic hypotension

  • Diabetes

  • Renal insufficiency

  • Hypertension

Biomarkers

  • Hemoglobin A1c

Drug/Treatment

  • Dapagliflozin

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • NCT01031680

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved